Item 8.01. Other Events.
On January 27, 2022, Galecto, Inc. (the "Company") issued a press release
announcing the publication of the full results of an investigator-initiated open
and randomized trial to evaluate the Company's inhaled galectin-3 inhibitor,
GB0139, in hospitalized patients with COVID-19 infection. A copy of the press
release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
99.1 Press Release, dated January 27, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses